What is Wedbush's Estimate for APLS Q3 Earnings?

Key Points

• Wedbush has raised its Q3 2025 EPS estimate for Apellis Pharmaceuticals to $1.42 per share, slightly up from the previous estimate of $1.41, while the consensus full-year earnings estimate is at a loss of $1.70 per share.
• Analysts' target prices for Apellis Pharmaceuticals vary significantly, with Scotiabank lowering their price target from $28.00 to $20.00, while Citigroup and Robert W. Baird raised theirs to $46.00 and $50.00, respectively.
• The stock has experienced a recent positive performance, opening at $22.95 with a market capitalization of $2.88 billion, but notable insider sales have occurred, including significant transactions by the general counsel and CEO.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at Wedbush increased their Q3 2025 EPS estimates for shares of Apellis Pharmaceuticals in a research report issued on Thursday, July 31st. Wedbush analyst L. Chico now anticipates that the company will earn $1.42 per share for the quarter, up from their prior estimate of $1.41. The consensus estimate for Apellis Pharmaceuticals' current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals' FY2027 earnings at $0.12 EPS, FY2028 earnings at $1.27 EPS and FY2029 earnings at $2.56 EPS.

A number of other analysts have also weighed in on APLS. Scotiabank decreased their target price on shares of Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating on the stock in a report on Thursday, May 8th. Citigroup upped their target price on shares of Apellis Pharmaceuticals from $41.00 to $46.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Robert W. Baird upped their target price on shares of Apellis Pharmaceuticals from $47.00 to $50.00 and gave the stock an "outperform" rating in a report on Friday, July 18th. Wall Street Zen raised shares of Apellis Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Cantor Fitzgerald increased their price target on shares of Apellis Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a report on Friday. Ten research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $37.78.

Apellis Pharmaceuticals Stock Performance

Shares of APLS stock opened at $22.95 on Monday. The stock has a market capitalization of $2.88 billion, a P/E ratio of -12.61 and a beta of 0.77. The company has a current ratio of 3.77, a quick ratio of 3.16 and a debt-to-equity ratio of 2.90. The firm's 50 day moving average is $18.76 and its 200 day moving average is $21.73. Apellis Pharmaceuticals has a 12 month low of $16.10 and a 12 month high of $41.94.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.11. The company had revenue of $171.39 million for the quarter, compared to analysts' expectations of $187.91 million. Apellis Pharmaceuticals had a negative net margin of 30.24% and a negative return on equity of 116.09%. Apellis Pharmaceuticals's revenue was down 10.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.30) EPS.

Insider Activity

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,000 shares of the company's stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $19.55, for a total transaction of $97,750.00. Following the completion of the sale, the general counsel directly owned 128,730 shares in the company, valued at $2,516,671.50. This represents a 3.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Cedric Francois sold 19,725 shares of the company's stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $20.21, for a total transaction of $398,642.25. Following the sale, the chief executive officer owned 331,605 shares of the company's stock, valued at approximately $6,701,737.05. The trade was a 5.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 169,090 shares of company stock valued at $3,403,832. Company insiders own 6.50% of the company's stock.

Institutional Trading of Apellis Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in APLS. AQR Capital Management LLC boosted its position in Apellis Pharmaceuticals by 119.6% during the 1st quarter. AQR Capital Management LLC now owns 4,077,419 shares of the company's stock valued at $89,173,000 after buying an additional 2,220,977 shares during the period. Boxer Capital Management LLC purchased a new stake in Apellis Pharmaceuticals during the 4th quarter valued at $45,504,000. Royal Bank of Canada boosted its position in Apellis Pharmaceuticals by 969.6% during the 4th quarter. Royal Bank of Canada now owns 1,518,827 shares of the company's stock valued at $48,465,000 after buying an additional 1,376,832 shares during the period. Point72 Asset Management L.P. purchased a new stake in Apellis Pharmaceuticals during the 4th quarter valued at $40,461,000. Finally, Avoro Capital Advisors LLC boosted its position in Apellis Pharmaceuticals by 10.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 12,222,222 shares of the company's stock valued at $390,011,000 after buying an additional 1,111,111 shares during the period. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.